Silencing miRNA‑1297 suppresses the invasion and migration of prostate cancer cells via targeting modulation of PTEN and blocking of the AKT/ERK pathway

Wang,Lei; Gao,Jing; Zhang,Yu; Kang,Shaosan

doi:10.3892/etm.2021.10200

Silencing miRNA‑1297 suppresses the invasion and migration of prostate cancer cells via targeting modulation of PTEN and blocking of the AKT/ERK pathway

Authors:
- Lei Wang
- Jing Gao
- Yu Zhang
- Shaosan Kang
View Affiliations

Affiliations: Department of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei 063000, P.R. China, Department of Obstetrics and Gynecology, Tangshan Hongci Hospital, Tangshan, Hebei 063000, P.R. China, Department of Intensive Care Units, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China
Published online on: May 17, 2021 https://doi.org/10.3892/etm.2021.10200
Article Number: 768
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phosphatase and tensin homolog (PTEN) loss is a major contributing factor of prostate cancer (PC). miRNA‑1297 was reported to serve role in various cancer types; however, the potential roles of miRNA‑1297 in PC had not been investigated. In the present study, tumor and adjacent tissues were collected from patients with PC. The gene expression level of miRNA‑1297 was measured via polymerase chain reaction. Results indicated that the miRNA‑1297 was overexpressed in tumor tissues from PC patients and in PC cell lines. miRNA‑1297 also contributed toward the progression of PC. PTEN was confirmed as the direct target of miRNA‑1297 and bound with miRNA‑1297 via four binding sites. The miRNA‑1297 level was negatively associated with the PTEN level. Silencing miRNA‑1297 or overexpression of PTEN significantly inhibited the cell migration and invasion. In addition, the AKT/ERK pathway was also inhibited following silencing of miRNA‑1297 or overexpression of PTEN. Taken together, the results indicated that silencing miRNA‑1297 exerted inhibitory effects on the invasion and migration of PC cells via modulating PTEN and blocking of the AKT/ERK pathway. The results of the present study provided a novel strategy for treatment of prostate cancer cells.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
2	Rani A, Dasgupta P and Murphy JJ: Prostate cancer: The role of inflammation and chemokines. Am J Pathol. 189:2119–2137. 2019.PubMed/NCBI View Article : Google Scholar
3	Mulholland EJ, Green WP, Buckley NE and McCarthy HO: Exploring the potential of microRNA Let-7c as a therapeutic for prostate cancer. Mol Ther Nucleic Acids. 18:927–937. 2019.PubMed/NCBI View Article : Google Scholar
4	Rawla P: Epidemiology of prostate cancer. World J Oncol. 10:63–89. 2019.PubMed/NCBI View Article : Google Scholar
5	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
6	Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et al: Prevention and early detection of prostate cancer. Lancet Oncol. 15:e484–e492. 2014.PubMed/NCBI View Article : Google Scholar
7	Pernar CH, Ebot EM, Wilson KM and Mucci LA: The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 8(a030361)2018.PubMed/NCBI View Article : Google Scholar
8	Grozescu T and Popa F: Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 10:5–12. 2017.PubMed/NCBI
9	Bertoli G, Cava C and Castiglioni I: MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 5:1122–1143. 2015.PubMed/NCBI View Article : Google Scholar
10	Qadir MI and Faheem A: miRNA: A diagnostic and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene Expr. 27:197–204. 2017.PubMed/NCBI View Article : Google Scholar
11	Tutar L, Özgür A and Tutar Y: Involvement of miRNAs and pseudogenes in cancer. Methods Mol Biol. 1699:45–66. 2018.PubMed/NCBI View Article : Google Scholar
12	Tutar Y: miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 15(429)2014.PubMed/NCBI View Article : Google Scholar
13	Van Roosbroeck K and Calin GA: Cancer hallmarks and MicroRNAs: The therapeutic connection. Adv Cancer Res. 135:119–149. 2017.PubMed/NCBI View Article : Google Scholar
14	Acunzo M and Croce CM: MicroRNA in cancer and cachexia-a mini-review. The J Infect Dis. 212 (Suppl 1):S74–S77. 2015.PubMed/NCBI View Article : Google Scholar
15	Fazio S, Berti G, Russo F, Evangelista M, D'Aurizio R, Mercatanti A, Pellegrini M and Rizzo M: The miR-28-5p targetome discovery identified SREBF2 as one of the mediators of the miR-28-5p tumor suppressor activity in prostate cancer cells. Cells. 9(354)2020.PubMed/NCBI View Article : Google Scholar
16	Zhu Z, Wen Y, Xuan C, Chen Q, Xiang Q, Wang J, Liu Y, Luo L, Zhao S, Deng Y and Zhao Z: Identifying the key genes and microRNAs in prostate cancer bone metastasis by bioinformatics analysis. FEBS Open Bio. 10:674–688. 2020.PubMed/NCBI View Article : Google Scholar
17	Tsai YS, Jou YC, Tsai HT, Shiau AL, Wu CL and Tzai TS: Prothymosin-α enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer. Cancer Sci. 110:1208–1219. 2019.PubMed/NCBI View Article : Google Scholar
18	Ullman D, Dorn D, Rais-Bahrami S and Gordetsky J: Clinical utility and biologic implications of phosphatase and tensin homolog (PTEN) and ETS-related gene (ERG) in prostate cancer. Urology. 113:59–70. 2018.PubMed/NCBI View Article : Google Scholar
19	Morais CE, Gurgel DC, Teixeira AC, Mattos TVA, Silva AVAd and Tavora F: Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort. Braz J Med Biol Res. 52:e8483. 2019.PubMed/NCBI View Article : Google Scholar
20	Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA and Netto GJ: Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 25:1543–1549. 2012.PubMed/NCBI View Article : Google Scholar
21	Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, et al: PTEN protein loss by immunostaining: Analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 17:6563–6573. 2011.PubMed/NCBI View Article : Google Scholar
22	Wang C, Feng Y, Zhang C, Cheng D, Wu R, Yang Y, Sargsyan D, Kumar D and Kong AN: PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer. FASEB J. 34:1304–1318. 2020.PubMed/NCBI View Article : Google Scholar
23	Yang NQ, Zhang J, Tang QY, Guo JM and Wang GM: miRNA-1297 induces cell proliferation by targeting phosphatase and tensin homolog in testicular germ cell tumor cells. Asian Pac J Cancer Prev. 15:6243–6246. 2014.PubMed/NCBI View Article : Google Scholar
24	Patel R, Gao M, Ahmad I, Fleming J, Singh LB, Rai TS, McKie AB, Seywright M, Barnetson RJ, Edwards J, et al: Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest. 123:1157–1175. 2013.PubMed/NCBI View Article : Google Scholar
25	Liauw SL, Kropp LM, Dess RT and Oto A: Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. Urol Oncol. 34:416. e415–421. 2016.PubMed/NCBI View Article : Google Scholar
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
27	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
28	Sun J, Li S, Wang F, Fan C and Wang J: Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis. BMC Med Genet. 20(191)2019.PubMed/NCBI View Article : Google Scholar
29	de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, Arranz Arija JA, Shih KC, Radavoi GD, Xu N, et al: Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin Cancer Res. 25:928–936. 2019.PubMed/NCBI View Article : Google Scholar
30	Wise HM, Hermida MA and Leslie NR: Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond). 131:197–210. 2017.PubMed/NCBI View Article : Google Scholar
31	Wang ZA, Toivanen R, Bergren SK, Chambon P and Shen MM: Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep. 8:1339–1346. 2014.PubMed/NCBI View Article : Google Scholar
32	Pietrzak K, Kuzyakiv R, Simon R, Bolis M, Bär D, Aprigliano R, Theurillat JP, Sauter G and Santoro R: TIP5 primes prostate luminal cells for the oncogenic transformation mediated by PTEN-loss. Proc Natl Acad Sci USA. 117:3637–3647. 2020.PubMed/NCBI View Article : Google Scholar
33	Chen Z, Zhang M, Qiao Y, Yang J and Yin Q: MicroRNA-1297 contributes to the progression of human cervical carcinoma through PTEN. Artif Cells Nanomed Biotechnol. 46 (Supp 2):S1120–S1126. 2018.PubMed/NCBI View Article : Google Scholar
34	Liang L, Feng L and Wei B: microRNA-1297 involves in the progression of oral squamous cell carcinoma through PTEN. Saudi J Biol Sci. 25:923–927. 2018.PubMed/NCBI View Article : Google Scholar
35	Chen X, Zhang L, Song Q and Chen Z: MicroRNA-216b regulates cell proliferation, invasion and cycle progression via interaction with cyclin T2 in gastric cancer. Anticancer Drugs. 31:623–631. 2020.PubMed/NCBI View Article : Google Scholar
36	Hu X, Tan S, Yin H, Khoso PA, Xu Z and Li S: Selenium-mediated gga-miR-29a-3p regulates LMH cell proliferation, invasion, and migration by targeting COL4A2. Metallomics. 12:449–459. 2020.PubMed/NCBI View Article : Google Scholar
37	Huang R, Li J, Pan F, Zhang B and Yao Y: The activation of GPER inhibits cells proliferation, invasion and EMT of triple-negative breast cancer via CD151/miR-199a-3p bio-axis. Am J Transl Res. 12:32–44. 2020.PubMed/NCBI
38	Wan P, Bai X, Yang C, He T, Luo L, Wang Y, Fan M, Wang Z, Lu L, Yin Y, et al: miR-129-5p inhibits proliferation, migration, and invasion in rectal adenocarcinoma cells through targeting E2F7. J Cell Physiol. 235:5689–5701. 2020.PubMed/NCBI View Article : Google Scholar
39	Jin W, Chen F, Wang K, Song Y, Fei X and Wu B: miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-beta signaling pathway. Biomed Pharmacother. 104:637–644. 2018.PubMed/NCBI View Article : Google Scholar
40	Yang F, Yu N, Wang H, Zhang C, Zhang Z, Li Y, Li D, Yan L, Liu H and Xu Z: Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9. PLoS One. 13(e0190725)2018.PubMed/NCBI View Article : Google Scholar
41	Mukherjee R, Bartlett JM, Krishna NS, Underwood MA and Edwards J: Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate. 64:101–107. 2005.PubMed/NCBI View Article : Google Scholar
42	Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 3:192–222. 2011.PubMed/NCBI View Article : Google Scholar
43	Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian H, Chen L, et al: MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett. 337:226–236. 2013.PubMed/NCBI View Article : Google Scholar
44	Zheng S, Wang S, Zhang Q, Zhang Z and Xu S: Avermectin inhibits neutrophil extracellular traps release by activating PTEN demethylation to negatively regulate the PI3K-ERK pathway and reducing respiratory burst in carp. J Hazard Mater. 389(121885)2020.PubMed/NCBI View Article : Google Scholar
45	Lu X, Xue B, Zhang T, Zhou X and Zhang Y: Down-regulation of microRNA-10a mediates the anti-tumor effect of icaritin in A549 cells via the PTEN/AKT and ERK pathway. Gen Physiol Biophys. 38:525–533. 2019.PubMed/NCBI View Article : Google Scholar